{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:40:08Z","timestamp":1791463208958,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12185-022-03490-x","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T13:29:36Z","timestamp":1668259776000},"page":"607-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage"],"prefix":"10.1007","volume":"117","author":[{"given":"Yuya","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-2782","authenticated-orcid":false,"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"3490_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5435\/00124635-200407000-00004","volume":"12","author":"JV Luck Jr","year":"2004","unstructured":"Luck JV Jr, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12:234\u201345.","journal-title":"J Am Acad Orthop Surg"},{"key":"3490_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/16078454.2022.2047286","volume":"27","author":"SA Tour\u00e9","year":"2022","unstructured":"Tour\u00e9 SA, Seck M, Sy D, Bousso ES, Faye BF, Diop S. Life-threatening bleeding in patients with hemophilia (PWH): a 10-year cohort study in Dakar. Senegal Hematology. 2022;27:379\u201383.","journal-title":"Senegal Hematology"},{"key":"3490_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/hae.13461","volume":"24","author":"EA Chalmers","year":"2018","unstructured":"Chalmers EA, Alamelu J, Collins PW, Mathias M, Payne J, Richards M, Paediatric and Rare Disorders Working Parties of the UK Haemophilia Doctors Organization, et al. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003\u20132015: a national cohort study. Haemophilia. 2018;24:641\u20137.","journal-title":"Haemophilia"},{"key":"3490_CR4","first-page":"378","volume":"17","author":"E Zanon","year":"2019","unstructured":"Zanon E, Pasca S. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus. 2019;17:378\u201384.","journal-title":"Blood Transfus"},{"key":"3490_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2516.2005.01123.x","volume":"11","author":"C Balkan","year":"2005","unstructured":"Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results from one centre. Haemophilia. 2005;11:463\u20137.","journal-title":"Haemophilia"},{"key":"3490_CR6","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1002\/pbc.24478","volume":"60","author":"C Ng","year":"2013","unstructured":"Ng C, Silliman CC, Pearl G, Smith W, Manco-Johnson M, Wang M. Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor. Pediatr Blood Cancer. 2013;60:E23\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"3490_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2516.2004.00924.x","volume":"10","author":"T Hayashi","year":"2004","unstructured":"Hayashi T, Tanaka I, Shima M, Yoshida K, Fukuda K, Sakurai Y, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia. 2004;10:397\u2013400.","journal-title":"Haemophilia"},{"key":"3490_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1365-2516.2010.02409.x","volume":"17","author":"R Grizelj","year":"2011","unstructured":"Grizelj R, Vukovi\u0107 J, Bili\u0107 E, Stern-Padovan R. Massive retroperitoneal haemorrhage in a neonate with severe haemophilia A. Haemophilia. 2011;17:547\u20138.","journal-title":"Haemophilia"},{"key":"3490_CR9","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570\u20134.","journal-title":"Nat Med"},{"key":"3490_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479","volume":"8","author":"Z Sampei","year":"2013","unstructured":"Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE. 2013;8: e57479.","journal-title":"PLoS ONE"},{"key":"3490_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjh.16964","volume":"191","author":"AA Barg","year":"2020","unstructured":"Barg AA, Livnat T, Budnik I, Avishai E, Brutman-Barazani T, Tamarin I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol. 2020;191:282\u201390.","journal-title":"Br J Haematol"},{"key":"3490_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27886","volume":"66","author":"AA Barg","year":"2019","unstructured":"Barg AA, Avishai E, Budnik I, Levy-Mendelovich S, Barazani TB, Kenet G, et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatr Blood Cancer. 2019;66: e27886.","journal-title":"Pediatr Blood Cancer"},{"key":"3490_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/hae.13877","volume":"26","author":"PT Ebbert","year":"2020","unstructured":"Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia. 2020;26:41\u20136.","journal-title":"Haemophilia"},{"key":"3490_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/hae.14212","volume":"27","author":"M Lewandowska","year":"2021","unstructured":"Lewandowska M, Randall N, Bakeer N, Maahs J, Sagar J, Greist A, et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US. Haemophilia. 2021;27:90\u20139.","journal-title":"Haemophilia"},{"key":"3490_CR15","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/jth.14022","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16:1078\u201388.","journal-title":"J Thromb Haemost"},{"key":"3490_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/jth.14135","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018;16:1383\u201390.","journal-title":"J Thromb Haemost"},{"key":"3490_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","volume":"115","author":"Y Nakajima","year":"2022","unstructured":"Nakajima Y, Mizumachi K, Shimonishi N, Furukawa S, Yada K, Ogiwara K, et al. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients. Int J Hematol. 2022;115:489\u201398.","journal-title":"Int J Hematol"},{"key":"3490_CR18","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jim\u00e9nez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127\u201338.","journal-title":"Blood"},{"key":"3490_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s12185-021-03108-8","volume":"113","author":"Y Nakajima","year":"2021","unstructured":"Nakajima Y, Tonegawa H, Noguchi-Sasaki M, Nogami K. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor. Int J Hematol. 2021;113:789\u201396.","journal-title":"Int J Hematol"},{"key":"3490_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1055\/s-0040-1710315","volume":"120","author":"Y Nakajima","year":"2020","unstructured":"Nakajima Y, Nogami K, Yada K, Furukawa S, Noguchi-Sasaki M, Hirata M, et al. Emicizumab improves ex vivo clotting function in patients with mild\/moderate hemophilia A. Thromb Haemost. 2020;120:968\u201376.","journal-title":"Thromb Haemost"},{"key":"3490_CR21","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s12185-022-03288-x","volume":"115","author":"F Kawahara","year":"2022","unstructured":"Kawahara F, Shirayama R, Ito T, Oshida K, Sato T, Kusuhara K. Hemophilic pseudotumor of the maxillary sinus in an inhibitor-positive patient with hemophilia A receiving emicizumab: a case report. Int J Hematol. 2022;115:906\u201312.","journal-title":"Int J Hematol"},{"key":"3490_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/TCRM.S4412","volume":"5","author":"JS Powell","year":"2009","unstructured":"Powell JS. Recombinant factor VIII in the management of hemophilia A: current use and future promise. Ther Clin Risk Manag. 2009;5:391\u2013402.","journal-title":"Ther Clin Risk Manag"},{"key":"3490_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/hae.14353","volume":"27","author":"JA Mason","year":"2021","unstructured":"Mason JA, Young G. Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making. Haemophilia. 2021;27:724\u20139.","journal-title":"Haemophilia"},{"key":"3490_CR24","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12185-021-03095-w","volume":"113","author":"K Mizumachi","year":"2021","unstructured":"Mizumachi K, Tsumura Y, Nakajima Y, Koh K, Nogami K. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis. Int J Hematol. 2021;113:930\u20135.","journal-title":"Int J Hematol"},{"key":"3490_CR25","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.3324\/haematol.2018.215129","volume":"104","author":"E Santagostino","year":"2019","unstructured":"Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica. 2019;104:e380\u20132.","journal-title":"Haematologica"},{"key":"3490_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-9560-13-1","volume":"13","author":"MD Lanc\u00e9","year":"2015","unstructured":"Lanc\u00e9 MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J. 2015;13:1.","journal-title":"Thromb J"},{"key":"3490_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","volume":"110","author":"K Yada","year":"2019","unstructured":"Yada K, Nogami K, Ogiwara K, Shida Y, Furukawa S, Yaoi H, et al. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol. 2019;110:419\u201330.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03490-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:40:13Z","timestamp":1744206013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03490-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3490"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03490-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Yamada has no disclosure of conflict of interest. Y. Nakajima has received grant from Takeda Pharmaceutical Co.. A. Ohara, E. Wakita, and K. Shimizu have no disclosure of conflict of interest. N. Shimonishi teaches a course endowed by CSL Behring. S. Furukawa taught a course endowed by CSL Behring, and has received personal fees from Chugai Pharmaceutical Co., Ltd., CSL Behring, and Takeda Pharmaceutical Co.. K. Ogiwara taught a course endowed by CSL Behring and has received personal fees from Chugai Pharmaceutical Co., Ltd. and CSL Behring. M. Takeyama has received personal fees from Chugai Pharmaceutical Co., Ltd. KM Biologics Co., Bayer AG, and CSL Behring. K. Nogami has received grants, personal fees, non-financial support from Chugai Pharmaceutical Co., Ltd., personal fees from F. Hoffmann-La Roche Ltd., grants, personal fees and non-financial support from Sysmex Co., grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Sanofi S.A, personal fees from CSL Behring Co., grants and personal fees from KM Biologics Co., grants and personal fees from Novo Nordisk A\/S, grants and personal fees from Bayer AG, grants and personal fees from Bioverativ Inc, and grants and personal fees from Shire Plc, and is an inventor of the patents relating to emicizumab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}